Roger Adsett - Insmed Chief Commercial Officer
| INSM Stock | USD 70.00 0.44 0.62% |
Executive
Mr. Roger Adsett serves as Chief Commercial Officer of the Insmed Inc. Mr. Adsett joined Insmed as Chief Commercial Officer in September 2016. Mr. Adsett has over 20 years of experience in the global biotechnology and pharmaceutical industry. From January 2015 to September 2016, Mr. Adsett was Senior Vice President, Head of Gastrointestinal and Internal Medicine Business Unit at Shire Plc, a global specialty biopharmaceutical company. From August 2008 to January 2015, Mr. Adsett was Senior Vice President, Gastrointestinal Business Unit Leader at Shire. From October 2005 to August 2008, Mr. Adsett was General Manager, Oral IBD Products of the Gastroenterology Business Unit of Shire. From November 1994 to October 2005, Mr. Adsett held various marketing and commercial roles at AstraZeneca plc, a multinational pharmaceutical and biopharmaceutical company. Mr. Adsett was a senior analyst at Accenture PLC, a global professional services company, from September 1991 to November 1994 since 2016.
| Age | 55 |
| Tenure | 8 years |
| Address | 700 US Highway 202/206, Bridgewater, NJ, United States, 08807 |
| Phone | 908 977 9900 |
| Web | https://www.insmed.com |
Latest Insider Transactions
Adsett holds a Masters of Business Administration from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in English and Economics from Bucknell University.Roger Adsett Latest Insider Activity
Tracking and analyzing the buying and selling activities of Roger Adsett against Insmed stock is an integral part of due diligence when investing in Insmed. Roger Adsett insider activity provides valuable insight into whether Insmed is net buyers or sellers over its current business cycle. Note, Insmed insiders must abide by specific rules, including filing SEC forms every time they buy or sell Insmed'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Roger Adsett over six months ago Disposition of 7857 shares by Roger Adsett of Insmed at 25.5 subject to Rule 16b-3 |
Insmed Management Efficiency
The company has return on total asset (ROA) of (0.2605) % which means that it has lost $0.2605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9075) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of December 2024, Return On Equity is likely to grow to 2.37, while Return On Tangible Assets are likely to drop (0.70). At this time, Insmed's Intangibles To Total Assets are very stable compared to the past year. As of the 23rd of December 2024, Debt To Assets is likely to grow to 0.91, though Net Tangible Assets are likely to grow to (127.7 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christian JD | Harmony Biosciences Holdings | N/A | |
| John Schembri | Akero Therapeutics | 62 | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| John Moore | Edgewise Therapeutics | 60 | |
| Melika Davis | BeiGene | N/A | |
| Yan Qi | BeiGene | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Jaspreet MD | BeiGene | N/A | |
| Michael LaBarre | Halozyme Therapeutics | 60 | |
| Arjun Natesan | Ultragenyx | N/A | |
| Christina MBA | Blueprint Medicines Corp | 48 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Dr MS | Fennec Pharmaceuticals | N/A | |
| Brenda Vreeswyk | Janux Therapeutics | N/A | |
| Kristin Schwartzbauer | Halozyme Therapeutics | N/A | |
| Arthur Levin | Avidity Biosciences | 70 | |
| W Flanagan | Avidity Biosciences | 61 | |
| Cortney MBA | Halozyme Therapeutics | N/A | |
| MS MD | Harmony Biosciences Holdings | N/A | |
| Audrey SPHR | Harmony Biosciences Holdings | N/A | |
| Jan Smith | Revolution Medicines | N/A | |
Management Performance
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.26 |
Insmed Inc Leadership Team
Elected by the shareholders, the Insmed's board of directors comprises two types of representatives: Insmed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insmed. The board's role is to monitor Insmed's management team and ensure that shareholders' interests are well served. Insmed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insmed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mandy Fahey, Executive Communications | ||
| Sara MBA, Chief Officer | ||
| Nicole MBA, Chief Officer | ||
| John Wise, Head VP | ||
| MBA JD, CEO President | ||
| Eleanor Barisser, Associate Relations | ||
| MD MBA, Chief Officer | ||
| Roger Adsett, Chief Commercial Officer | ||
| John III, VP Officer | ||
| Kevin MD, Head Development | ||
| Paul MD, Advisor | ||
| John MBA, Chief Officer | ||
| Nicole Schaeffer, Sr. VP of HR and Corporate Services | ||
| Michael Smith, Sr Counsel | ||
| Michael JD, Chief Secretary | ||
| Roger MBA, Chief Officer | ||
| Brian Kaspar, Chief Officer | ||
| Neil Hughes, Middle Europe | ||
| MD FCCP, Chief Officer |
Insmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insmed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.52) % | ||||
| Operating Margin | (2.13) % | ||||
| Current Valuation | 12.13 B | ||||
| Shares Outstanding | 178.9 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 99.09 % | ||||
| Number Of Shares Shorted | 12.62 M | ||||
| Price To Earning | (8.70) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.